




Healthcare Industry News: neurostimulator
News Release - July 30, 2018
BlueWind Medical Appoints Dr. Roger R. Dmochowski, MD, MMHC, as Chief Medical Officer
HERZLIYA, Israel, July 30, 2018 -- (Healthcare Sales & Marketing Network) -- BlueWind Medical, a developer of a miniature, wireless neurostimulation platform for the treatment of multiple clinical indications, announced today the appointment of Dr. Roger R. Dmochowski of Vanderbilt University as the company's chief medical officer (CMO). Dr. Dmochowski will be leading clinical efforts, including the upcoming OASIS (OverActive bladder StImulation System study) pivotal trial of RENOVA iStim™ for the management of overactive bladder (OAB). The study is expected to commence in early 2019, with an overall target of 250 patients to be implanted with RENOVA iStim™ in up to 25 medical centres in several European countries."I am extremely pleased to be able to provide medical oversight to the clinical trial of the RENOVA iStim™, which I believe will have a significant positive impact on patients' lives," said Dr. Dmochowski.
"We are delighted to formally welcome Dr. Dmochowski to our team, and we are certain he will add great value to BlueWind through his knowledge, experience and enthusiasm," commented Guri Oron, BlueWind's CEO.
About BlueWind Medical
BlueWind Medical was founded in 2010 by Rainbow Medical. The company is developing a platform technology of miniature, wireless, neurostimulators that can be injected or implanted in a minimally invasive procedure to treat multiple indications. By putting patients' needs first, BlueWind Medical's team of experienced and dedicated engineers and researchers are creating a versatile and effective platform that will transform neuromodulation as we know it.
About Rainbow Medical
Rainbow Medical (http://www.rainbowmd.com ) is a unique private operational investment company that seeds and grows start-up companies developing breakthrough medical devices, addressing significant unmet market needs in a diverse range of medical fields.
Source: BlueWind Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.